Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacodynamics
6 evidence topics · 5 sources
Circulating insulin as a biomarker of exposure: healthy volunteers
Reduced insulin sensitivity after single infusions: healthy volunteers
“X358-dependent increases in postprandial glucose levels and fasting homeostatic model assessment of insulin resistance values were observed and persisted for at least 1 week at the higher dose levels.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In all the ITT cohorts, the slope for glucose lowering was substantially attenuated after X358 infusion of a similar magnitude, but with increasing duration with rising dose level.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Single X358 infusions were well tolerated and resulted in a dose-dependent reduction in insulin sensitivity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Insulin biomarker response in congenital hyperinsulinism
Inhibition of IGF-2 signaling at the insulin receptor: in vitro studies
Reversal of insulin-induced hypoglycemia in mice: XMetD
“Intraperitoneal injection of XMetD at 10 mg/kg twice weekly into normal mice induced insulin resistance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When sustained-release insulin implants were placed into normal mice, they developed fasting hypoglycemia in the range of 50 mg/dl.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This hypoglycemia was reversed by XMetD treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevention of fasting hypoglycemia in a mouse model of KATP hyperinsulinism
“SUR-1−/− and wild-type mice received twice weekly intraperitoneal injections of either XMetD or control antibody for 8 wks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment with XMetD significantly decreased insulin sensitivity, and increased hepatic glucose output and fasting plasma glucose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote